Tamtam Try Tamtam free
Roche logo

Roche account plan

Personalized healthcare and innovation

At a glance

Roche is a Basel-based pharmaceuticals and diagnostics group with CHF 61.5 billion of 2025 sales and 112,774 employees.

Roche is a Basel-based healthcare group with two divisions, Pharmaceuticals and Diagnostics, focused on oncology, neurology and cardiovascular-metabolic diseases, among other areas. In 2025 Group sales rose 7% at constant exchange rates (CER) to CHF 61,516 million, core operating profit rose 13% to CHF 21,833 million and IFRS net income rose 58% to CHF 13.8 billion. The group treated more than 39 million patients with its medicines and delivered 31 billion diagnostic tests in 2025. It employed 112,774 people (headcount), 53,638 of them in Europe and 27,594 in North America. Severin Schwan chairs the board and Thomas Schinecker is CEO.

Business units

Strategic priorities

20 transformative medicines by 2029
The pharma strategy aims to bring 20 transformative medicines to patients by 2029; ten had been delivered by end-2025, and 19 medicines could launch by the end of the decade.
R&D Excellence and pipeline
Ten molecules entered phase III in 2025, a record, including trontinemab (Alzheimer's) and zosurabalpin; the pipeline holds 66 new molecular entities, with 66% of the late-stage portfolio having best-in-disease potential against an 80% target.
Obesity and cardiovascular-metabolic
CT-388 (enicepatide) phase III started in 2026, petrelintide with Zealand Pharma received a phase III go, and the 89bio acquisition adds pegozafermin for MASH.
Diagnostics growth platforms
Predictive CGM, fully automated mass spectrometry, SBX sequencing (a potential CHF 1 billion-plus product), blood-based Alzheimer's tests and AI algorithms; target of mid single digit growth in 2026 and mid-to-high single digit in 2027.
Margin and AI in development
Roche intends to expand Group margin in 2026 and keep it at least stable thereafter, with R&D broadly flat and AI used across the development process.

Latest results

In H1 2026 Group sales were CHF 30,364 million, up 6% at CER but down 2% in Swiss francs, as the strong franc cut 8 points from sales. Core operating profit rose 10% CER to CHF 11,856 million (margin 39.0%) and core EPS 9% to CHF 10.85, while IFRS net income fell 6% to CHF 7,325 million after CHF 1.0 billion of impairments. Pharmaceuticals sales were CHF 23,629 million (+6%), led by Xolair, Hemlibra, Ocrevus and Phesgo; Diagnostics sales were CHF 6,735 million (+3%), with China down 15%. Free cash flow was CHF 4,197 million and net debt rose to CHF 22.1 billion after CHF 8.3 billion of dividends. Guidance for 2026 was confirmed: mid single digit sales growth and high single digit core EPS growth at CER, with a higher dividend.

Investments and deals

USD 50 billion US investment
USD 50 billion over five years in US R&D and manufacturing, including USD 2 billion in CVRM manufacturing at Holly Springs, CGM manufacturing in Indianapolis and a Boston research hub, linked to a three-year tariff exemption.
Building 12 in Basel
A CHF 500 million R&D centre whose construction began in 2025.
2026 acquisitions
SAGA Dx for USD 408 million (molecular residual disease), PathAI for about USD 750 million plus up to USD 300 million (AI pathology), and USD 700 million upfront for Nurix's BTK degrader.
Partnerships
51 new partnerships in 2025, including the Zealand Pharma petrelintide deal and the agreement to acquire 89bio.
Restructuring
Restructuring costs of CHF 765 million in H1 2026 for R&D optimisation, business process transformation and organisational effectiveness.

Challenges and risks

Biosimilar erosion
Products with expired patents fell CHF 0.7 billion in 2025; the first US Xolair biosimilars are expected from H2 2026 and Perjeta biosimilars from 2027 in Europe.
China pricing reforms
Reforms cut Diagnostics sales in Asia-Pacific by 12% in 2025 and China Diagnostics sales by 15% in H1 2026.
Currency
Swiss franc strength cut 8 points from H1 2026 sales and 11 points from core operating profit.
Tariffs and costs
US tariffs raised Diagnostics cost of sales, which absorbed about 43 million of tariffs in H1 2026.
Competition in key brands
Competition in anti-CD20 slows Ocrevus, Tecentriq faces competition in Europe and the US branded eye-care market contraction weighs on Vabysmo.

What leadership says

“We always said we will deliver, and we delivered”

Thomas Schinecker, CEO Roche Group · Full Year 2025 results webinar, 29 January 2026

“we do not expect a patent cliff”

Teresa Graham, CEO Roche Pharmaceuticals · Full Year 2025 results webinar, 29 January 2026

“usually we were not the highest bidder when we won the deals”

Thomas Schinecker, CEO Roche Group · Half Year 2026 results webinar, 23 July 2026

“a company reveals its true strength in a challenging environment”

Severin Schwan, Chairman, and Thomas Schinecker, CEO · Letter in the Annual Report 2025, January 2026

Where a supplier can help

US manufacturing and R&D build-out
The USD 50 billion US programme, including Holly Springs and Indianapolis plants, creates demand for construction, equipment, automation and supply-chain partners.
Clinical trial capacity
Ten new phase III programmes and R&D efficiencies reallocated to phase III point to CRO, site and trial technology suppliers.
AI in development and pathology
AI used throughout development and the PathAI acquisition open room for data, AI and digital pathology integration partners.
Cost and margin programmes
Restructuring for business process transformation and the goal to expand margin fit process automation and efficiency services.
Diagnostics launches
SBX sequencing, mass spectrometry and CGM launches need manufacturing, distribution and lab-workflow partners to scale.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Roche?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Roche

What does Roche do?

Roche develops and sells prescription medicines and diagnostic tests and instruments, with a focus on oncology, neurology, immunology, ophthalmology and cardiovascular-metabolic diseases.

What is Roche's revenue?

Group sales were CHF 61,516 million in 2025, up 7% at constant exchange rates; H1 2026 sales were CHF 30,364 million.

How many employees does Roche have?

Roche employed 112,774 people (headcount) at the end of 2025.

Who leads Roche?

Thomas Schinecker is CEO of the Roche Group and Severin Schwan is Chairman; Teresa Graham leads Pharmaceuticals and Matt Sause Diagnostics.

What is Roche's strategy?

Bringing 20 transformative medicines to patients by 2029, a record late-stage pipeline including obesity, and growth platforms in diagnostics such as sequencing and mass spectrometry.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)